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A Midcourse Assessment of Hantavirus
Pulmonary Syndrome
 Our understanding of infectious diseases
follows a natural coursethe initial discovery of
the cause, the exploration of the natural history
and biology of the etiologic agent, and finally the
cure or solution. The discovery of Sin Nombre
virus (SNV), one of the viruses causing
hantavirus pulmonary syndrome (HPS), is
unparalleled in terms of the rapid progress of the
scientific investigation leading to its description.
A cluster of cases of fatal adult respiratory
syndrome was recognized in the Four Corners
region of the United States in May 1993, and
within a few days serologic evidence confirmed
hantavirus infection (1). The outbreak occurred
in the wake of the Institute of Medicines report
Emerging Infections: Microbial Threats to Health
in the United States, in which acute respiratory
disease was first on the list of clinical syndromes
requiring high-priority surveillance (2).
The scientific community has now entered
the midcourse phase of HPS research, including
the exploration of the natural history of the
American hantaviruses. Seven articles in this
issue describe studies of rodent reservoirs of Sin
Nombre and related viruses. They illustrate the
multidisciplinary nature of such studies, which
require ecologic methods, in addition to the
newer molecular biology techniques that have
helped hantavirologists detect and characterize
the viruses.
These and other studies have elucidated
much about the natural host relationships of
hantaviruses. Multiple hantavirus genotypes
exist in virtually all parts of North and South
America; each hantavirus genotype has a single
rodent species as its principal reservoir.
Evidence exists that the virus and rodent have
evolved together. Each hantavirus variant is
focal in distribution. Prevalence of antibody is
high in some regions, and low or absent in others,
even when the same species of rodent is found in
both places. Rodents are not infected at birth;
they acquire the virus from other rodents. Once
infected, the animals develop antibody, but
many, or maybe all, infected rodents remain
infected. Because of rapid turnover of the rodent
population (as older antibody-carrying animals
die and nonimmune animals are born), antibody
prevalence can vary greatly, from 0% to 50%,
with prevalence often lower than 20%.
The studies also have raised new questions.
Why and by what route are animals infected?
The articles in this issue suggest that
contamination of wounds when animals fight
may be an important route of infection, while
allowing for the possibility of secondary
mechanisms, such as venereal transmission or
close association during communal nesting.
Although textbooks state that people become
infected by inhaling aerosols created by the
rodents, we need better information. If the
animals create infectious aerosols, why are only
a small proportion of susceptible animals
infected, even in enclosed colonies of the rodents
(3)? Why is human infection so rare, even among
forest workers and mammalogists (4)? Are some
animals supersecretors of virus? Are individual
virus-carrying rodents infectious for life or only
periodically? If periodically, what makes them
shed and stop shedding virus?
Classic pathogenesis studies are required to
answer these questions. Two technologic
advancesreverse transcription-polymerase
chain reaction (RT-PCR) and enzyme-linked
immunosorbent assay (ELISA)have revolu-
tionized science but at the same time lured us
away from other time-tested methods. Before the
RT-PCR technique was developed, virologists
measured infectious virus by isolating it in cell
cultures or laboratory animals. Although we
need information about the infectivity of rodent
blood, urine, throat secretions, feces, and
organs, few investigators attempt to isolate
infectious hantaviruses. The reasons are
obvious. Virus isolation is tedious, technically
difficult, and (without biosafety level three or
four facilities) dangerous. Because detecting
nucleic acid by RT-PCR is safe and easily
accomplished, most investigators are satisfied
with that method. Safe isolation of hantaviruses
in the Americas will require additional
investment in physical biocontainment facilities
for university and government laboratories.
Many compelling reasons exist for isolating
hantaviruses. How else will serotype specificity,
animal models, pathogenic potential, replica-
tion, transmission, and other phenotypic
properties be studied? I cannot emphasize too
strongly the importance of propagating and
preserving this biologic material. To isolate
hantaviruses from rodent tissues will require
new approaches. The technical difficulty now in173 Vol. 5, No. 1, JanuaryFebruary 1999 Emerging Infectious Diseases
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isolating hantaviruses is analogous to that
encountered 30 years ago with dengue viruses.
The solution for dengue was to use a natural
host, the mosquito (5). Colonized, virus-free
rodent reservoir hosts of hantaviruses could
possibly provide the increased sensitivity to
infection needed to facilitate routine isolation of
hantaviruses. This approach has been successful
on a limited scale in Europe (6).
Only two serologic methodsELISA and, to
a lesser extent, immunofluorescence assayare
used on a large scale in the Americas for testing
rodent sera for hantavirus antibody. CDC
developed a recombinant antigen product of the
small RNA segment of SNV (7), which was
produced in large quantity and distributed gratis
to state health departments and to collaborators
in both North and South America for use in
ELISA. The antigen is broadly cross-reactive and
entirely safe. Before the advent of ELISA, classic
virologists surveyed for antibody with one test
and then confirmed a portion of the antibody-
positive and -negative serum specimens with a
different test, often the neutralization test. Such
confirmatory tests are desirable in the studies of
rodents for hantavirus antibody but are rarely
done. The neutralization test, used to a limited
extent (8), is not practical for study of large
numbers of rodent serum specimens or for work
with biosafety level four agents. An alternate to
this test is the hemagglutination-inhibition test.
Asian and European hantaviruses agglutinate
goose cells (9,10); it should be feasible, therefore,
to develop the hemagglutination-inhibition test
for American hantaviruses.
What will it take to cure or prevent HPS? The
only proposed antihantavirus drug is ribavirin,
which although still under trial, has not been
efficacious in treating HPS (11). Supportive
emergency care can save lives, but diagnosis
must be made early, clinical expertise is
concentrated in only a few medical centers, and
HPS cases are often dispersed. Approaches to
hantavirus human vaccines have been developed
(12), but such vaccines are probably not
commercially feasible in the Americas, which
have a low incidence of disease caused by focal
genotypes. Rodent control does not seem
practical because of the immense geographic
range of hantaviruses. Ongoing rodent studies
may eventually determine whether a wildlife
vaccine analogous to that used successfully for
rabies will be practical (13).
For the immediate future, we must depend
on education to prevent human exposure. To
design an effective education program, we must
know much more about the rodent reservoir and
the mode of virus transmission, both among
rodents and to people. The publication of these
ecologic studies in a medical journal represents
important changes in the medical and ecologic
sciences. These studies have required collabora-
tion of ecologists, epidemiologists, and virolo-
gists. Their successful continuation, as well as
the conception, design, and conduct of future
studies, requires the spirit of innovation best
achieved in a multidisciplinary atmosphere, as
well as a long-term commitment to collect data
for several years.
Robert E. Shope
University of Texas Medical Branch, Galveston,
Texas, USA
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